Cite
HARVARD Citation
Cree, B. et al. (2020). Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet neurology. 19 (12), pp. 988-997. [Online].